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Many orphan diseases have been identified that indi-
vidually affect small numbers of patients but cumula-
tively affect w6%–10% of the European and United
States populations. Human genetics has become in-
creasingly effective at identifying genetic defects
underlying such orphan genetic diseases, but little
progress has been made toward understanding the
causal molecular pathologies and creating targeted
therapies. Chemical genetics, positioned at the inter-
face of chemistry and genetics, can be used for eluci-
dation of molecular mechanisms underlying diseases
and for drug discovery. This review discusses re-
cent advances in chemical genetics and how small-
molecule tools can be used to study and ultimately
treat orphan genetic diseases.We focus here on a case
study involving spinal muscular atrophy, a pediatric
neurodegenerative disease caused by homozygous
deletion of the SMN1 (survival of motor neuron 1) gene.
Introduction
There arew6,000 diseases that individually affect fewer
than 200,000 patients in the United States, but that cu-
mulatively have profound effects on the health of many
people (http://rarediseases.info.nih.gov/html/reports/
fy2003/FY2003_index.html). The pharmaceutical indus-
try, faced with the large costs of drug discovery and de-
velopment, generally neglects these diseases due to the
paucity of patients. In 1983, the Orphan Drug Act (ODA)
was enacted to promote the development of therapeu-
tics for these orphan diseases by offering incentives
to the pharmaceutical industry such as fee waivers,
tax credits, and market exclusivity for 7 years [1]. Con-
gress reevaluated the rare disease research environ-
ment in 2002 and discovered that, in spite of the
positive outcomes from the ODA, ‘‘rare diseases and
disorders [deserve] greater emphasis in the national
biomedical research enterprise’’ [2].
In response to these conclusions, Congress passed
the Rare Diseases Act (RDA) of 2002. The act increased
government investment in the development of diagnos-
tic tools and therapeutics for rare diseases by legisla-
tively establishing the Office of Rare Diseases at the
National Institutes of Health (NIH) and specifically desig-
nating appropriations for the study of rare diseases [2].
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With both the ODA and the RDA enacted, academia
and industry were financially primed to identify, analyze,
optimize, formulate, and market targeted therapeutics
for rare diseases. Unfortunately, the scientific commu-
nity possessed little knowledge about nearly all of these
diseases. Recent scientific advances in many fields
have, however, improved our knowledge of these dis-
eases and our approach to understanding them. The
advent of modern human genetics has revealed that
many of the w6,000 rare diseases are genetic in origin
[3]. These diseases include Huntington’s disease, spinal
muscular atrophy (SMA), amyotrophic lateral sclerosis
(ALS, or Lou Gehrig’s disease), Tourette syndrome,
Crohn disease, cystic fibrosis, cystinosis, Duchenne
muscular dystrophy, thallasemias, hemophilia, and
rare cancers, such as sarcomas.
One approach to understanding genetic diseases
involves using high-throughput cellular assays to find
organic compounds that interact functionally, not phys-
ically, with disease alleles. This approach, using small
molecules to perturb protein networks of biological sys-
tems, is referred to as chemical genetics by analogy to
model organism genetics (classical genetics). Chemical
genetics is a potential route to elucidating the cellular
and molecular mechanisms of disease pathogenesis.
Here, we discuss how this approach has been applied
to the pediatric autosomal recessive disease spinal
muscular atrophy, and how small molecules may aid in
understanding and treating orphan genetic diseases.
Advances in Biology
In the late eighteenth century, plant extracts were shown
to exhibit various effects on animals. Shortly after, Fred-
erick Serturner isolated morphine from the opium plant
in 1804 [4], indicating that biologically active molecules
do indeed exist in nature. When Paul Ehrlich discovered
that methylene blue selectively stains neuronal cells, he
revealed that small molecules have specific biological
targets [5, 6]. He won the 1908 Nobel Prize in Medicine
for his work, and the term he coined, receptor, has re-
mained valuable ever since. Even though these con-
cepts—which represent the theoretical keystones of
chemical genetics—were first articulated more than
200 years ago, chemical genetics required many subse-
quent advances to reach its current status as a powerful,
alternative approach to classical genetics.
Modern human genetics flourished in the latter half of
the twentieth century with the discovery of the structure
of DNA (1953) [7], the breaking of the genetic code
(1967) [8, 9], the discovery of reverse transcriptase
(RT) (1970) [10, 11], the advent of recombinant DNA
technology (1973) [12], and the introduction of polymer-
ase chain reaction (PCR) (1985) [13]. These advances,
coupled with linkage analysis techniques as well as
with functional and positional cloning, have permitted
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in disease pathogenesis [14, 15]. Using this approach,
the first disease-causing gene—the X-linked gene for
chronic granulomatous disease—was positionally
cloned in 1986 [16]. This analysis also permitted the dis-
covery of common polymorphisms such as the e4 allele
of the APOE gene (ApoE4 protein) on chromosome 19
[17], which increases susceptibility to late-onset Alz-
heimer disease [18].
Knowledge of the genome increased in the twenty-
first century, when 99% of the euchromatic human ge-
nome was sequenced in 2004 [19]. With simple data-
base operations, this blueprint now permits rapid
identification of genes and their mutated alleles, includ-
ing detection of single nucleotide polymorphisms
(SNPs). Modern gene cloning and knockout techniques
allow for the generation of human genetic disease mod-
els in lower organisms such as fruit flies (Drosophila
melanogaster), zebrafish (Danio rerio), or mice (Mus
musculus). Phenotypic effects of gene modulation
(e.g., overexpression, silencing) can easily be obtained
from these models.
Unfortunately, these models in lower organisms rarely
recapitulate the full spectrum of disease in humans.
Human cell-based models of genetic diseases are com-
plementary and can be engineered using molecular
biology; these genetic-like models permit subsequent
study of disease on a molecular and cellular level. How-
ever, correcting a cellular disease phenotype is difficult,
as implicated proteins are often either novel or do not
have a known small-molecule modulator.
First applied in a systematic fashion in the 1990s,
chemical genetics is a potential approach for the study
of genetic diseases [20–22]. Like classical genetics,
this approach seeks to uncover the specific macromole-
cules (usually proteins) that act as critical regulators of
cellular processes, whose functions are subsequently
defined using protein biochemistry, molecular cell biol-
ogy, and a significant amount of chemical synthesis.
Chemical genetics offers advantages over the classical
genetic approach: small molecules can permit research-
ers to temporally control modification of protein function
by adding and washing away the small molecule and to
specifically affect only one function of a multifunctional
protein. Used in human cellular disease models, this ap-
proach offers a genetic-like method for studying human
diseases and, in some cases, for uncovering novel ther-
apeutic candidates. Chemical genetic approaches have
indeed uncovered small molecules that ameliorate or
rescue genetic diseases, including the rescue of mutant
V2 vasopressin receptors (V2R) associated with nephro-
genic diabetes insipidus [23], the chaperoning of proper
b-glucosidase folding for Gaucher disease patients [24],
and the restoration of signaling via mutant vitamin D
Table 1. Rare Diseases Definitions
Country/Organization Definition of Rare Disease
Australia <2,000 Australians
European Community (EC) <5:10,000 inhabitants
Japan <4:10,000 Japanese
United States <200,000 Americans
World Health Organization 0.65–1:1,000 peoplereceptors (VDR) in patients with hereditary vitamin
D-resistant rickets (HVDRR) [25].
Advances in Chemistry, Engineering,
and Computing
In traditional genetic screens, an effective muta-
gen (e.g., ultraviolet light) creates random mutations
throughout the genome. Similarly, chemical genetics re-
quires an effective collection of small molecules to per-
turb protein networks. Useful molecules are specific for
a single target, have high intrinsic activity (i.e., com-
pletely inhibit or activate a target), and are potent. Ideal
libraries contain small molecules that are (1) structurally
complex (i.e., rigid like most natural products with
known biological targets) to decrease the entropic
cost of binding a target and (2) diverse (i.e., contain
many chemical scaffolds) to facilitate the presentation
of functional groups for interactions with targets.
Although rule sets have facilitated the selection of
small molecules for screening, two difficulties remain:
(1) creating sufficient structural diversity to ensure com-
pounds interact with many different target proteins and
(2) synthesizing large numbers of compounds for
screening. The advent of diversity-orientated synthesis
(DOS) and combinatorial syntheses offer solutions to
these problems. DOS profits from the already existing
practicality, efficiency, and scale of split-pool synthesis
[26] but incorporates reactants to produce a compound
collection that is both diverse and structurally and iso-
merically complex [27]. With careful planning, large
numbers of both diverse and complex molecules have
been synthesized using few synthetic steps with DOS
methodology in which products of one reaction are
the substrates of the subsequent reaction [28, 29].
Have optimal regions of chemical space already been
defined by nature? Or has nature simply synthesized the
best small molecules possible using chemical function-
alities that were readily available? If the latter is true,
then the ability to create diverse natural product-like
compounds that have not been evolutionarily selected
for is perhaps one of the most interesting prospects of
modern synthetic organic chemistry. This process lends
itself to discovering novel regulators of gene products
for which no naturally occurring small molecule exists.
Chemical screens necessitate multiple tests to main-
tain quality control. High-throughput automated screen-
ing pipelines incorporate innovations in robotics, ma-
terials engineering, and computer science to help
accommodate this need. Advanced liquid handling
(ALH) robotic systems and microtiter platereaders,
both in 384-well format, have significantly increased
screening throughput while lowering the cost per exper-
iment. Miniaturization (to 96-well, 384-well, and micro-
array format [30]) has, however, created new problems,
including media evaporation, accumulation of toxins,
nutrient depletion, and the need for advanced detection
systems for assay execution.
Conventional testing of small-molecule libraries in
replicate creates hundreds of thousands of data points
and presents a remarkable challenge in terms of both
organizational bookkeeping and data analysis. Using
plate barcodes for tracking each compound and its
linked data, data analysis software facilitates the orga-
nization and analysis of compound structures, physical
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data [31]. Following normalization, the systematic spa-
tial errors that are common with modern robotics can
be automatically detected and corrected [32]. Compu-
tational analyses are performed, and active compounds
are highlighted for subsequent study. Hit compounds
undergo secondary screening, which typically includes
confirmation in a different assay and a counter screen
to eliminate possible artifacts (e.g., fluorescent com-
pounds) that presented in the primary screen.
Assay Development and Target Identification
With compound libraries and an automated screening
pipeline available, laboratories must develop an effec-
tive, sensitive assay that models the disease of interest.
Although, in theory, many biological questions and dis-
eases can be studied using a chemical approach, devel-
oping a specific assay that is amenable to high-
throughput screening may be problematic. Financial
constraints can additionally limit the types of assays
that can be used (e.g., high-content, image-based as-
says require an automated microscope and image anal-
ysis software). Two broad categories of screens are
possible: target-based or phenotype-based.
Target-based screens involve the same concept as
reverse genetics. Commonly used by pharmaceutical
companies, this type of screen involves the identifica-
tion, isolation, and purification of the specific protein
(i.e., small-molecule target) to be studied. With the avail-
ability of entire genome DNA sequences, it may be pos-
sible in some cases to perform this type of screen against
all members ofa protein family. Target-basedassayshave
discovered small-molecule partners for numerous pro-
teins, such as helicases [33], E3 ubiquitin ligases [34],
steroid receptors [35], transglutaminases [36], coagula-
tion factors [37], and T cell costimulatory receptors [38].
Phenotype-based screens, on the other hand, are
comparable to forward genetic screens (Figure 1).
Whole cells are exposed to small molecules until a phe-
notype of interest is found. Phenotypes may be detected
through functional assays that measure various cellular
activities, such as apoptosis, cell division, or adhesion
to a substrate. Other assays, such as reporter gene as-
says or immunofluorescence, involve the detection of
a specific marker indicating the phenotypic change. Re-
cently, phenotype-based assays have discovered small
molecules that modulate cell cycle arrest [39, 40], en-
hance melanin production [41], prevent cell migration
[42], prevent IL-6 secretion [43], prevent progression in
Figure 1. Chemical Genetic Pipeline
In forward phenotype-based chemical genetic screens, cells (1) and
small organic molecules (2) are dispensed into 384-well microtiter
plates. After incubation, an appropriate assay (e.g., cell viability) is
executed, and the phenotype of interest is identified (3). Hit com-
pounds enter secondary testing, including testing in dilution series
(4) and other confirmatory methods. Medicinal chemistry optimiza-
tion and testing of analogs (5) identifies the most active structure.
Disease model organisms (6) provide a final confirmation of desired
phenotype and permit initial observation of compound-induced sys-
temic effects. Affinity purification techniques can be used to identify
the macromolecule target of the small molecule (7) providing mech-
anistic information. Drug development includes studying and opti-
mizing toxicity, pharmacokinetics, and pharmacodynamics (8)
before moving to formulation and clinical testing (9).
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The survival of motor neuron (SMN) protein is a ubiquitously expressed protein found in all somatic tissues (1). Unaffected humans possess
two nearly identical copies of the SMN (survival of motor neuron) gene at locus 5q13 (2). A single nucleotide difference inside exon 7 of SMN2
(3) causes alternative pre-mRNA splicing that results in truncation (i.e., lacking exon 7) of w75% of the final SMN2 mRNA transcripts (com-
pared to SMN1) (4). Most patients with spinal muscular atrophy have a homozygous deletion of SMN1. SMN2 transcripts may not be functional
and their protein products may be rapidly degraded (red X). Full-length transcripts are translated into functional SMN protein (5) (SMN tudor
domain is shown). SMN protein, in conjunction with other proteins, has been implicated in the biogenesis of small nuclear ribonucleoproteins
(snRNPs) (6) and growth cone localization with axon pathfinding (7). (Number 7 is reproduced from The Journal of Cell Biology, 2003, volume
162(5), p. 923, by copyright permission from The Rockefeller University Press.)mitosis [44], and kill tumor cells in a genotype-specific
fashion [45]. These assays can be used to screen thou-
sands of molecules, which may be used as therapeutic
candidates for disease treatment and as chemical tools
to perturb disease protein networks.
After finding a small molecule that affects a cellular
process and produces the desired phenotype, the chal-
lenge remains of identifying the small-molecule target
or targets. Fifteen years after chemical genetic studies
began in earnest, target identification is still a challenge.
At its onset, scientists using chemical screening ap-
proaches had success with this arduous task (e.g., puri-
fication of calcineurin as the target of FK506 [46], histone
deacetylase (HDAC) as the target of trapoxin [47], and tu-
bulin as the target of colchicine [48]). The same affinity
purification techniques applied then continue to be
used today; this usually entails immobilizing the active
small molecule on a solid resin (e.g., plastic bead) for
subsequent incubation with cellular lysate, elution
of nonspecific proteins, purification, and sequencing of
bound target proteins. Several opinions have been of-
fered to explain the infrequent success of this approach:
attachment of the small molecule to a solid support ei-
ther requires a vital functional group or affects the re-
quired molecular confirmation, steric hindrance of the
compound-target interaction is involved, or low binding
affinity prohibits target isolation [49]. With some suc-
cesses using this classic pull-down experiment, new
modifications are under development, including creating
chimeric ligands [50, 51], developing new binding assays
that properly compete with the target [52], comparing
proteinsbound toa true target to those bound toa ‘‘false’’
molecule (e.g., structural analog, ideally an enantiomer)
[53, 54], and using a photo-inducible linker to covalently
link the molecule to its target in vivo [55].
Spinal Muscular Atrophy
SMA is a fatal, autosomal recessive, pediatric disease
that results in rapid degeneration and death of a-motorneurons in the anterior horn of the spinal cord. SMA is
the leading genetic cause of infant (under 2 years of
age) mortality in the United States and Western Europe,
with an incidence of w1:6,000 live births and a carrier
frequency of 1:40 [56, 57]. Certain populations (e.g.,
Saudi), however, have higher rates due to consanguine-
ous marriages [58]. No cure or treatment exists for SMA.
The small numbers of patients with this genetic disease
have resulted in a lack of interest from the pharmaceu-
tical industry despite the scientific tractability of SMA
relative to most other orphan genetic diseases. Studies
of the underlying molecular pathology of SMA have the
potential to reveal essential aspects of motor neuron
function and functions of the gene product, and also
to suggest various therapeutic strategies for this dis-
ease [20, 21, 59].
The SMN1 (survival of motor neuron 1) gene codes for
a 294 amino acid, 38 kD, essential, ubiquitously ex-
pressed protein (Figure 2). Humans possess two nearly
identical copies of this gene (SMN1 and SMN2) located
on a 500 kb inverted repeat in a relatively unstable re-
gion of the genome at locus 5q13 [60]. These two genes
differ only in five nucleotides within their coding regions,
none of which alter the predicted amino acid sequence
but do alter the pre-mRNA splicing [61].
In humans, the archetypal primary mRNA (pre-mRNA)
transcript contains many introns (i.e., non-protein cod-
ing sequences) and exons (i.e., protein coding sequen-
ces). The spliceosome is composed of several small
nuclear ribonucleoproteins (snRNPs) that form the com-
plex required to catalyze splicing, a post-transcriptional
process that removes introns from the primary tran-
script and ligates exons to form a final mRNA transcript
suitable for translation.
Nucleotide polymorphisms and/or mutations in both
intronic and exonic sequences can affect splicing.
These sequence changes may create cis-regulatory
elements, such as an exonic splicing enhancer (ESE)
or an intronic splicing enhancer (ISE). ESEs stimulate
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promote removal of the intron. In fact, alternative forms
of pre-mRNA splicing exist for w74% of multiexon
genes [62]. Alternative splicing is the major source of
proteomic diversity in eukaryotic organisms [63]. Ex-
pectedly, alternative splicing can adversely affect the
gene product (e.g., truncation, poor folding). This can
be, in certain instances, the sole cause of disease, or
it can modulate a disease phenotype. Uncovering meth-
ods of regulating aberrant splicing represents a largely
unexplored avenue for therapeutic development.
The MAPT gene, which encodes the microtubule-
associated protein TAU, can be spliced into six different
isoforms in the human brain. A proper ratio of isoforms
is required to prevent development of chromosome 17’s
frontotemporal dementia with parkinsonism (FTDP-17)
[64, 65]. Similarly, various isoforms of the CFTR (cystic
fibrosis transmembrane conductance regulator) gene
cause the typical cystic fibrosis pulmonary disease,
as well as male sterility and pancreatic deficiency [66,
67]. Alternative splicing also plays a role in spinal mus-
cular atrophy patients.
One hundred percent of the pre-mRNA transcript
from the telomeric gene SMN1 (or SMNT) produces
full-length mRNA with eight exons. A single C-to-T tran-
sition at position six in exon 7 of SMN2 (or SMNC)
causes alternative pre-mRNA splicing that is 75%–
80% effective, resulting in a truncated mRNA (usually
lacking exon 7) and protein product. SMN2 transcripts
may not be functional and their protein products may
be rapidly degraded, although this is disputed by
some investigators. There is also current debate as to
whether this nucleotide difference disrupts an exonic
splice enhancer (ESE) [68, 69] or creates an exonic
splice suppressor (ESS) [70]. Translation of SMN2,
therefore, yields four to five times less full-length SMN
protein as is produced from SMN1. SMA patients have
either a homozygous deletion of, or a mutation in, the
SMN1 gene and are therefore left with a level of full-
length SMN protein that is not sufficient to preserve
function and life of a-motor neurons [71, 72]. Synthetic
activators directed to specific pre-mRNA targets have
been proposed as emerging technologies with thera-
peutic potential for SMA [73].
Mice, on the other hand, have a single SMN gene (de-
noted Smn), which produces a gene product that is 82%
identical in sequence to human SMN protein [74, 75].
This gene is expressed as early as embryonic day 7
[74]. Homozygous deletion of this gene causes early
embryonic lethality [76]. Addition of a human SMN2
transgene into an Smn2/2 background rescues this
lethality, but the pups rapidly develop SMA pathology
after birth [77, 78], indicating that SMN protein is essen-
tial through at least postnatal day 1.
In humans, SMA presents phenotypically with proxi-
mal, symmetrical, lower limb and trunk muscle weak-
ness, muscular atrophy, paraplegia, and, frequently,
early childhood death. The International SMA Consor-
tium has defined three types of juvenile-onset SMA,
based on severity and time of onset [79]. Type I
(Werdnig-Hoffman disease; OMIM #253300) is the
most severe and the most common (w50% of SMA pa-
tients); it is characterized by disease onset before 6
months of age and death before 2 years. Children withtype I SMA are unable to sit without assistance. The
second chronic form of SMA, type II (OMIM #253550),
is of intermediate severity, with onset before 18 months
of age and death after two years. Type II patients are
able to sit but cannot walk or stand without help. Type
III (Kugelberg-Welander disease; OMIM #253400), the
least severe, is distinguished by disease onset after 18
months of age. Type III patients reach all landmarks in
motor development and are able to walk until muscles
atrophy; they live into adulthood. Pearn et al. have char-
acterized a very rare, type IV SMA (OMIM #271150) that
presents during adulthood, between 20 and 50 years of
age. Type IV patients experience some difficulty walking
but have a normal life expectancy [80, 81]. Due to the
rareness of this SMA variant, it has not been subject
to significant study, although gene conversions [82] or
deletions of exons seven and eight [83, 84] have been
reported with this variant.
Full-length SMN protein level has been shown to in-
versely correlate with SMA severity (patient life span,
time of onset, symptoms). Moreover, Feldko¨tter and
colleagues recently reported a striking correlation be-
tween SMA type and SMN2 copy number in humans
[85], which can be greater than two due to gene duplica-
tion and conversion events [86–88]. Of type I SMA pa-
tients, 80% possessed one or two copies of SMN2;
82% of type II patients had three SMN2 copies; and
96% of patients with type III SMA carried three or four
copies of SMN2. This correlation was further shown in
Smn2/2 mice with eight copies of a human SMN2 trans-
gene; these were phenotypically normal and lived nor-
mal lives [77, 78]. However, other modifier genes may
exist as well [89].
Since the isolation of the SMN gene product in 1995
[61], SMN protein has been subject to intense scrutiny
in hopes of understanding disease pathogenesis
through protein-protein interactions, as well as the struc-
ture and localization of the protein itself. SMN protein,
which is expressed at particularly high levels in neurons
[90], is diffusely localized in the cytoplasm and in small,
SMN-containing, nuclear punctate structures called
gems. SMN protein has been implicated in the bio-
genesis of snRNPs involved in spliceosome formation
[91, 92] and in axon pathfinding with localization in the
axon growth cones [93, 94].
SMA and Phenotype-Based Screens
In hopes of elucidating the molecular mechanism of
SMA disease pathogenesis and uncovering therapeutic
options for SMA patients, research groups have re-
cently pursued various methods of upregulating the
SMN2 promoter [95], correcting alternative SMN2 pre-
mRNA splicing [96–99], preventing the degradation of
SMN protein [100], and modulating SMN2 translation
[101]. These laboratories have chosen a partially hy-
pothesis-based approach, in which tested compounds
were chosen for a previously reported effect (e.g.,
HDAC inhibition) that would putatively have a similar ef-
fect on SMN protein regulation. Specifically, hydroxy-
urea was recently reported as a candidate SMA ther-
apeutic. Chosen for its strong safety profile, high
pediatric bioavailability, and known gene upregulation,
hydroxyurea was found to restore exon 7 inclusion in
SMN2 transcripts, as well as increasing both SMN
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patient lymphoblastoid cell lines [96]. Knowing that the
SMN protein carboxyl terminus is critical for proper lo-
calization, Lorson and colleagues discovered several
aminoglycosides, known to suppress stop codon iden-
tification, that cause the SMND7 protein to acquire five
additional amino acids [101]. This addition increases
SMN protein expression and the number of nuclear
gems in SMA patient cells.
Several laboratories, including ours, have embarked
on high-throughput screening of diverse, small-molecule
libraries using phenotype-based screens to discover
regulators of SMN protein production. This approach
has yielded novel regulators of SMN protein that may
serve as both drug leads and as new chemical tools to
probe the regulation system of SMN protein. It should
be noted that, although decreases in SMN protein level
result in lower gem counts, small molecules may alter
SMN protein distribution between the nucleus and the
cytoplasm or affect the time that SMN protein resides
in gems. An increase in residency time offers a possible
explanation why some compounds exhibit large gem
count increases with modest SMN protein upregulation
(see below).
In 2001, Andreassi and colleagues reported that
aclarubicin (aclacinomycin A), an old topoisomerase-
based oncology drug, promotes the retention of exon
7 in the SMN2 transcript in type I SMA patient fibro-
blasts (3813) and in a mouse motor neuron-like cell
line (NSC34) [102]. Using a semiquantitative RT-PCR
assay [71], 960 compounds of the Microsource Plus li-
brary had been screened. While aclarubicin is a known
chemotherapy agent and possesses a toxicity profile
incompatible with a treatment regiment for SMA pa-
tients, its discovery indicates that high-throughput as-
says can be used to study splicing modifications, and
it may be valuable in studying other diseases with alter-
native splicing. In addition, this compound may serve
as a probe to identify mechanisms regulating SMN2
splicing.
Using an assay designed to detect exon 7 inclusion in
the SMN2 transcript, we reported a screen of 47,062
compounds that could affect the production of SMN
protein [103]. The small molecules screened were from
four libraries: a combinatorial chemistry library (Com-
Genex), a National Institute for Neurological Disorders
and Stroke (NINDS) library, our Annotated Compound
Library of known bioactive molecules [104], and our
TIC library of compounds selected for specific proper-
ties including stereocomplexity, saturated heterocycles,
and other natural product qualities. This screen resulted
in two selective compounds: aclarubicin (discovered
previously, as described above) and indoprofen, a non-
steroidal anti-inflammatory drug (NSAID) and cyclooxy-
genase (COX) inhibitor.
Indoprofen was the only NSAID that exhibited this ef-
fect on SMN protein production, indicating that its ac-
tion does not implicate COXs. Surprisingly, real time
RT-PCR (qRT-PCR) revealed no change in either the ab-
solute level or the ratio of full-length to truncated SMN2
mRNA transcript from indoprofen-treated type I SMA
patient fibroblasts (3813). Indoprofen treatment did,
however, modestly increase endogenous SMN protein
level in 3813 cells and caused an increase in the numberof nuclear gems. To confirm indoprofen’s effect, the
ability of indoprofen to rescue embryonic lethality in
an SMA mouse model was examined: an increase in
mean litter size and a trend showing increased viability
of SMA model mice resulted. Indoprofen may serve as
a possible therapeutic candidate for SMA patients and
may be developed into a tool for probing mechanisms
governing SMN protein production.
Recently, Jarecki and colleagues used a b-lactamase
reporter gene assay to detect increases in SMN2 tran-
scription [105]. Driven by a 3.4 kb fragment of the endo-
genous promoter, fluorescence produced by cleavage
of a b-lactamase substrate was read from NSC34 cells
treated with w550,000 synthetic compounds. Two
chemical scaffolds (an indole and a quinazoline) ex-
hibited significant increases in exon 7 inclusion in the
SMN2 transcript and increased production of SMN pro-
tein as quantified by Western blot. Only the quinazoline,
however, was amenable to medicinal chemistry (i.e., re-
tained activity after modification). Both scaffolds are un-
dergoing medicinal chemistry optimization for drug-like
characteristics before entering animal testing and sub-
sequent clinical trails.
Several compounds have been found to ameliorate
SMA pathogenesis by upregulating SMN2 transcription
[106], modulating pre-mRNA splicing of the SMN2 tran-
script [96, 97, 99, 102, 105], or upregulating SMN protein
through an unknown mechanism [103]. All of the poten-
tial therapeutics for SMA induce a modest SMN protein
or gem count increase in SMA patient cells and have
shortcomings that range from gastrointestinal bleeding
to short half-life in human serum, and from high toxicity
to upregulation of hundreds of genes (Figure 3). There
is no additional evidence to indicate that these com-
pounds will improve existing SMA pathology or prevent
disease pathogenesis in vivo. While the initial data are
promising [107, 108], the effects of these small mole-
cules in SMA clinical trials remain to be determined.
Additionally, determining how much SMN protein is
needed, along with proper spatial and temporal data,
to rescue the SMA phenotype are critically important
outstanding questions that need attention.
A complementary approach to SMA drug discovery
involves searching for small molecules that replace or
enhance the function of the SMN protein. For example,
Dreyfuss and colleagues have pioneered this approach
and developed an assay to find such compounds [109].
Such SMN-replacing compounds would be comple-
mentary to those that enhance production of SMN pro-
tein from the SMN2 gene, and together these two types
of compounds might yield a powerful combination
therapy.
Undoubtedly, additional small molecules with thera-
peutic potential in SMA remain undiscovered. The fu-
ture of chemical genetics, as it relates to spinal muscu-
lar atrophy, is 2-fold: first, the mechanism of action of
reported candidate therapeutics should be elucidated
by using the small molecule itself as a chemical tool in
target-identification assays, such as affinity purification
and mRNA binding assays. In addition, putative HDAC
inhibitors, such as valproic acid, can be profiled for their
specificity against all HDAC family members. Identified
target(s) will influence the design of future target-based
assays to uncover more effective (i.e., more potent,
Review
1069Figure 3. Candidate Therapeutics for SMA
Patients
(A) Sodium butyrate [99], (B) sodium 4-phe-
nylbutyrate [106], (C) indoprofen [103], (D)
valproic acid [97, 98], (E) hydroxyurea [96],
(F) aclarubicin [102], and (G) amikacin (a rep-
resentative aminoglycoside) [101] have all
been reported to ameliorate SMA pathogen-
esis through known and unknown mecha-
nisms. FDA approval status and possible
shortcomings of each candidate small mole-
cule are presented.higher intrinsic activity) small molecules. Virtual screen-
ing (the in silico counterpart of high-throughput screen-
ing) promises to be a popular approach to determining
functionalities predicted to bind to such protein targets
[110–112]. Second, new phenotype-based assays will
be developed to detect increases in SMN protein level
or gem count, or compounds that otherwise overcome
the effects of SMN1 deletion, which are the sought-after
activities of candidate therapeutics. Such assays have
been developed for other proteins [39, 71, 113–115].
Coupled with libraries composed of small molecules se-
lected for disease-specific applications (e.g., ability to
cross the blood-brain barrier for neurological diseases),
these assays will identify new molecules to use as
chemical tools for probing the SMN protein regulation
system in addition to being candidate drugs.
Future Improvements and Outlook
Small molecules play vital roles at the cellular level, but
the downstream effects manifest at all levels of biolog-
ical organization (i.e., cell, tissue, organ, system, organ-
ism). Despite the presence of small molecules in
essentially every aspect of life, small molecules have
yet to be included in the ‘central dogma’ (DNA to RNA
to protein) [116]. Recent advances have outfitted the
scientific community with the technologies needed to
explore biological processes using chemical tools.Chemical genetics applies these advances to studying
human genetic diseases and simultaneously developing
therapeutic candidates. However, important challenges
remain to be solved.
The throughput of screening assays must be im-
proved to allow for the testing of larger numbers of com-
pounds, which should lead to the discovery of more
potent compounds. Several possibilities exist for in-
creasing screening throughput: (1) eliminating the
required spatial separation of compounds and (2) re-
taining the spatial separation but designing more effi-
cient detection methods. New nonspatial approaches
involve encoded self-assembling chemical (ESAC) li-
braries [117], which enable novel small molecules to be
uncovered in target-based screens. Using this method-
ology, small molecules linked to oligonucleotide
sequences undergo self-assembly in vitro to form a
library in which rapid compound identification is done
via standard PCR amplification. On the other hand, spa-
tial separation can be preserved if detection methods
are developed with sufficient sensitivity to be quantifi-
able. Recently, a novel microarray technique for pheno-
type-based screens was created that embeds small
molecules into polymer spots (w200 mm in diameter)
on a standard microscope slide [30]. Using a biodegrad-
able polymer, the small molecule is slowly released, and
the phenotypic effects of cells growing over the slide can
Chemistry & Biology
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croscopy, coupled with computational algorithms, will
allow less compound (and fewer cells) to be used in
screens.
The medical community frequently treats diseases
with several drugs. Correspondingly, this combination
therapy approach has already proven to be valuable in
high-throughput screens [118, 119]. This multicompo-
nent, systems-based method can uncover synergistic
therapeutics while providing information about pathway
crosstalk. However, determining which small molecules
to screen in combination and interpreting the results of
such screens in terms of underlying mechanism remain
largely untapped areas of research.
As a long-range outlook, several ‘‘audacious goals’’
for chemical biology were recently proposed [116].
These include cataloging all naturally occurring small
molecules, discovering a small molecule that modulates
every individual function of human proteins, and linking
the genotype of cells to the phenotypic response(s) eli-
cited by small molecules. Over the coming years, both
‘biological-activity space’ and ‘chemical-activity space’
will be further mapped and linked in pursuit of these
goals [120]. RNA interference (RNAi) [121, 122], antibod-
ies [123], and gene expression analysis [124] will com-
plement study with small molecules. The complete
realization of these goals will renovate and rejuvenate
science, medicine, and orphan disease research.
Conclusion
The chemical genetic approach to studying human dis-
ease pathogenesis has evolved over the last 15 years.
Despite this progress, many challenges remain. The fa-
tal pediatric disease spinal muscular atrophy is an ex-
ample in which successful phenotype-based screens
using high-throughput screening technologies have
been applied to study of a rare disease. Several upregu-
lators of SMN protein have been discovered, and addi-
tional compounds will likely emerge in the near future.
With many rare genetic diseases in human popula-
tions, both the political and scientific communities
need to embrace the challenge to identify and define
therapeutic candidates for disease treatment. With a
concerted effort, academics, nonprofit organizations,
and industrial groups can work together to develop the
equipment, technologies, and assays needed for in-
vestigating these devastating and neglected human
diseases.
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